A copy of the poster is available at the following link: ESMO Poster May 2025 More information about the data CytoDyn presented at ESMO suggesting the novel mechanism of action of leronlimab for ...

Avacta’s proprietary pre|CISION® chemistry ... to recent benchmarking data in this patient population presented at ESMO 2024, with a reported PFS of 3.5 months (15 weeks) in a large cohort ...

is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting, following its promising survival ...